Urgent need to develop independent biomarkers for functional, diagnostic and prognostic application in oncology research

Biomarkers in Medicine

Volumn 3, Issue 4, 2009, Pages 329-333

  Foster, Christopher S ^a   Cooper, Colin S ^b  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALK NPM FUSION PROTEIN; ANDROGEN RECEPTOR; HEAT SHOCK PROTEIN 20; HEAT SHOCK PROTEIN 27; HYBRID PROTEIN; ISOCITRATE DEHYDROGENASE; PROTEIN P53; TMPRSS2 ETS FUSION PROTEIN; TRANSCRIPTION FACTOR ELK 4; TUMOR MARKER; UNCLASSIFIED DRUG;

CANCER DIAGNOSIS; DNA DETERMINATION; EARLY CANCER; EDITORIAL; FUSION GENE; GENE MUTATION; GENE STRUCTURE; HUMAN; PROGNOSIS; PROSTATE CANCER; PROTEIN INTERACTION;

EID: 70549086957     PISSN: 17520363     EISSN: None     Source Type: Journal    
DOI: 10.2217/bmm.09.25     Document Type: Editorial

References (33)

1. Brown G, Greaves MF, Lister TA, Rapson N, Papamichael M: Expression of human T and B lymphocytes cell-surface markers on leukaemic cells. Lancet 2, 753-755 (1974).
2. Futreal PA, Coin L, Marshall M et al.: A census of human cancer genes. Nat. Rev. Cancer 4, 177-183 (2004).
3. Cooper CS, Foster CS: Concepts of epigenetics in prostate cancer development. Br. J. Cancer 100, 240-245 (2009).
4. Hamilton RJ, Goldberg KC, Platz EA, Freedland SJ: The influence of statin medications on prostate-specific antigen levels. J. Natl Cancer Inst. 100, 1511-1518 (2008).
5. Parrado C, Falkmer UG, Hoog A et al.: A technique for automatic/initeractive assessment of the proliferating fraction of neoplastic cells in solid tumors. A methodological study on the Ki-67 immunoreactive cells in human mammary carcinomas, including a comparison with the results of conventional S-phase fraction assessments by means of DNA cytometry. Gen. Diagn. Pathol. 141, 215-227 (1996). (Pubitemid 26099878)
6. Nowell P, Hungerford D: A minute chromosome in human chronic granulocytic leukemia (abstract). Science 132, 1497 (1960).
7. Tomlins SA, Rhodes DR, Perner S et al.: Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310, 644-648 (2005). (Pubitemid 41528150)
8. Tomlins SA, Laxman B, Dhanasekaran SM et al.: Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature 448, 595-599 (2007). (Pubitemid 47206938)
9. Rickman DS, Pflueger D, Moss B et al.: SLC45A3-ELK4 is a novel and frequent erythroblast transformation-specific fusion transcript in prostate cancer. Cancer Res. 69, 2734-2738 (2009).
10. Clark J, Attard G, Jhavar S et al.: Complex patterns of ETS gene alteration arise during cancer development in the human prostate. Oncogene 27, 1993-2003 (2008).
11. Attard G, Clark J, Ambroisine L et al.: Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer. Oncogene 27, 253-263 (2008).
12. Pulford K, Falini B, Cordell J et al.: Biochemical detection of novel anaplastic lymphoma kinase proteins in tissue sections of anaplastic large cell lymphoma. Am. J. Pathol. 154, 1657-1663 (1999). (Pubitemid 29262847)
13. Wang W, El-Deiry: WS Restoration of p53 to limit tumor growth. Curr. Opin. Oncol. 20, 90-96 (2008). (Pubitemid 350190987)
14. Zache N, Lambert JM, Rokaeus N et al.: Mutant p53 targeting by the low molecular weight compound STIMA-1. Mol. Oncol. 2, 70-80 (2008).
15. Zhao S, Lin Y, Xu W et al.: Gliomaderived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1α. Science 324, 261-265 (2009).
16. Steinkamp MP, O'Mahony OA, Brogley M et al.: Treatment-dependent androgen receptor mutations in prostate cancer exploit multiple mechanisms to evade therapy. Cancer Res. 69(10), 4434-4442 (2009).
17. Bukach OV, Glukhova AI, SeitNebi AS, Gusev NB: Heterooligomeric complexes formed by human small heat shock proteins HspB1 (Hsp27) and HspB6 (Hsp20). Biochim. Biophys. Acta 1794, 486-495 (2009).
18. Burgess AW: EGFR family: structure physiology signalling and therapeutic targets. Growth Factors 26, 263-274 (2008).
19. 111In. J. Nucl. Med. 50, 582-590 (2009).
20. Hahn Y, Bera Tk, Gehlhaus K et al.: Finding fusion genes resulting from chromosome rearrangement by analyzing the expressed sequence databases. Proc. Natl Acad. Sci. USA 101, 13257-13261 (2004). (Pubitemid 39209652)
21. Ahmed S, Thomas G, Ghoussaini M et al.: Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2. Nat. Genet. 41(5), 585-590 (2009).
22. Cox C, Bignell G, Greenman C et al.: A survey of homozygous deletions in human cancer genomes. Proc. Natl Acad. Sci. USA 102, 4542-4547 (2005). (Pubitemid 40397148)
23. Mavaddat N, Dunning AM, Ponder BA, Easton DF, Pharoah PD: Common genetic variation in candidate genes and susceptibility to subtypes of breast cancer. Cancer Epidemiol. Biomarkers Prev. 18, 255-259 (2009).
24. Swanton C, Caldas C: Molecular classification of solid tumors: towards pathway-driven therapeutics. Br. J. Cancer 100(10), 1517-1522 (2009).
25. Diehl F, Schmidt K, Choti MA et al.: Circulating mutant DNA to assess tumor dynamics. Nat. Med. 14, 985-990 (2008).
26. Cissell KA, Deo SK: Trends in microRNA detection. Anal. Bioanal. Chem. 394(4), 1109-1116 (2009).
27. Leite KR, Sousa-Canavez JM, Reis ST et al.: Change in expression of miR-let7c, miR-100 and miR-218 from high grade localized prostate cancer to metastasis. Urol. Oncol. doi: 10.1016/j.urolonc.2009.02.002 (2009) (Epub ahead of print).
28. Gnjatic S, Old LJ, Chen YT: Autoantibodies against cancer antigens. Methods Mol. Biol. 520, 11-19 (2009).
29. Dehainault C, Michaux D, Pages-Berhouet S et al.: A deep intronic mutation in the RB1 gene leads to intronic sequence exonisation. Eur. J. Hum. Genet. 15, 473-477 (2007). (Pubitemid 46487702)
30. Korneeva I, Bongiovanni AM, Girotra M, Caputo TA, Witkin SS: IgA antibodies to the 27-kDa heat-shock protein in the genital tracts of women with gynecologic cancers. Int. J. Cancer 87, 824-828 (2000). (Pubitemid 30660562)
31. Sjoblom T, Jones SA, Wood LD et al.: The consensus coding sequences of human breast and colorectal cancers. Science 314, 268-274 (2006). (Pubitemid 44571966)
32. Jones SA, Zhang X, Parsons DW et al.: Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321, 1801-1806 (2008).
33. McLendon R, Friedman A, Bigner D et al.: Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455, 1061-1068 (2008).